Morgan Stanley’s New York Life Investments ETF Trust NYLIM U.S. Large Cap R&D Leaders ETF LRND Stock Holding History

Morgan Stanley’s Portfolio LRND Stock Details LRND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$54	Hold	1	–	–	﹤0.01%	8077
2026 Q1	$41	Buy	+1	New	+$40	﹤0.01%	8019
2025 Q3	–	Sell	-1	Closed	-$46	–	8279
2025 Q2	$46	Buy	+1	New	+$33	﹤0.01%	7810

Other funds holding LRND

NYLIM

New York Life Investment Management New York $14.3B AUM 34.42% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Sankala Group Lyons, Colorado $150M AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Morgan Stanley's LRND Position: Q2 2026 in Review

Morgan Stanley held its New York Life Investments ETF Trust NYLIM U.S. Large Cap R&D Leaders ETF (LRND) position steady in Q2 2026 at 1 share worth $54. The position accounts for ﹤0.01% of the portfolio, ranked #8077.

Morgan Stanley first reported a position in LRND in Q2 2025 and has held it in 3 quarters since. 6 funds tracked by Wall St. Rank hold LRND as of Q2 2026.

Morgan Stanley held 1 share of New York Life Investments ETF Trust NYLIM U.S. Large Cap R&D Leaders ETF worth $54 as of Q2 2026.
Morgan Stanley left its New York Life Investments ETF Trust NYLIM U.S. Large Cap R&D Leaders ETF share count unchanged in Q2 2026.
New York Life Investments ETF Trust NYLIM U.S. Large Cap R&D Leaders ETF made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #8077 holding.
Morgan Stanley first reported a position in New York Life Investments ETF Trust NYLIM U.S. Large Cap R&D Leaders ETF in Q2 2025 and has held it in 3 quarters since.
6 funds tracked by Wall St. Rank held New York Life Investments ETF Trust NYLIM U.S. Large Cap R&D Leaders ETF as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.